{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:20:42Z","timestamp":1793424042557,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/ftd.0000000000000238","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T20:08:17Z","timestamp":1440619697000},"page":"79-86","source":"Crossref","is-referenced-by-count":16,"title":["Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method"],"prefix":"10.1097","volume":"38","author":[{"given":"Runfeng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxia","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1040-8428(98)00036-5","article-title":"Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancerstatus of the art.","volume":"30","author":"Gamelin","year":"1999","journal-title":"Crit Rev Oncol Hematol"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":". Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.","volume":"94","author":"Baker","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/bjc.2013.262","article-title":". Pharmacogenetic variants in the dpyd, tyms, cda and mthfr genes are clinically significant predictors of fluoropyrimidine toxicity.","volume":"108","author":"Loganayagam","year":"2013","journal-title":"Br J Cancer"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","article-title":"Dosing strategies for anticancer drugs: the good, the bad and body-surface area.","volume":"38","author":"Felici","year":"2002","journal-title":"Eur J Cancer"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clcc.2011.03.015","article-title":". Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on folfox regimens.","volume":"10","author":"Saam","year":"2011","journal-title":"Clin Colorectal Cancer"},{"key":"R6-11-20210129","first-page":"2039","article-title":". Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.","volume":"4","author":"Fety","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1989.59","article-title":". 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer.","volume":"59","author":"Santini","year":"1989","journal-title":"Br J Cancer"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1998.16.4.1470","article-title":". Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.","volume":"16","author":"Gamelin","year":"1998","journal-title":"J Clin Oncol"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":". Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.","volume":"101","author":"Saif","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00280-003-0658-0","article-title":". Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.","volume":"52","author":"Ychou","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1200\/JCO.2004.03.119","article-title":". Randomized multicenter phase II trial of bolus plus infusional fluorouracilleucovorin compared with fluorouracilleucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.","volume":"22","author":"Kemeny","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-07-1529","article-title":". 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.","volume":"14","author":"Di Paolo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","article-title":". A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.","volume":"19","author":"Patel","year":"2014","journal-title":"Oncologist"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4161\/cbt.12.7.18059","article-title":". Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-fu) levels during dose optimization of infusional 5-fu in colorectal cancer patients.","volume":"12","author":"Kline","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":". Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/FTD.0b013e3181b9b8c0","article-title":". Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer.","volume":"31","author":"Beumer","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","article-title":". Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.","volume":"17","author":"Kaldate","year":"2012","journal-title":"Oncologist"},{"key":"R19-11-20210129","first-page":"2347","article-title":". Clinical randomized study of 5fu monitoring versus standard dose in patients with head and neck cancer: preliminary results.","volume":"14","author":"Fety","year":"1994","journal-title":"Anticancer Res"},{"key":"R21-11-20210129","first-page":"439","article-title":". Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion.","volume":"80","author":"Wihlm","year":"1993","journal-title":"Bull Cancer"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clcc.2012.05.004","article-title":". Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.","volume":"11","author":"Capitain","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clcc.2013.11.001","article-title":". Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.","volume":"13","author":"Kline","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"R24-11-20210129","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2012.08.015","article-title":". A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy.","volume":"414","author":"Sistonen","year":"2012","journal-title":"Clin Chim Acta"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3816\/CCC.2004.n.003","article-title":". Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracilleucovorin chemotherapy in colorectal cancer.","volume":"3","author":"Zhu","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":". DPYD IVS141GA and 2846AT genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clcc.2013.12.001","article-title":"Pharmacokinetically guided dose adjustment of 5-fu-a critical element toward personalized medicine.","volume":"13","author":"Goel","year":"2014","journal-title":"Clin Colorectal Cancer"},{"key":"R28-11-20210129","first-page":"1437","article-title":"Pharmacokinetic adaptation of 5-fuorouracil: where are we and where are we going Pharmacogenomics.","volume":"13","author":"Boisdron-Celle","year":"2012","journal-title":""},{"key":"R29-11-20210129","first-page":"241","article-title":"Blood and urine levels of antitumor agents determined with cell culture methods.","volume":"25","author":"Smith","year":"1965","journal-title":"Cancer Res"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/clinchem\/25.1.83","article-title":". Comparison of liquid and gas-liquid chromatographic assays of 5-fluorouracil in plasma.","volume":"25","author":"Christophidis","year":"1979","journal-title":"Clin Chem"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","article-title":". A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.","volume":"29","author":"Ciccolini","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/rcm.3362","article-title":". Quantitation of 5-fluorouracil (5-fu) in human plasma by liquid chromatographyelectrospray ionization tandem mass spectrometry.","volume":"22","author":"Kosovec","year":"2008","journal-title":"Rapid Commun Mass Spectrom"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:29:50Z","timestamp":1620952190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201602000-00011"}},"subtitle":["A Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000238","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}